1
|
Ribeiro PAF, Souza MQ, Dias DS, Álvares ACM, Nogueira LM, Machado JM, Dos Santos JC, Godoi RR, Nobrega YKM, Campos-da-Paz M, de Freitas SM, Felipe MSS, Torres FAG, Galdino AS. A Custom-Designed Recombinant Multiepitope Protein for Human Cytomegalovirus Diagnosis. Recent Pat Biotechnol 2019; 13:316-328. [PMID: 31333134 DOI: 10.2174/1872208313666190716093911] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 06/17/2019] [Accepted: 07/28/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND The Human Cytomegalovirus (HCMV) has infected more than 90% of the world population and its prevalence can be related to the individuals geographical and socialeconomic status. Serological tests based on ELISA are pivotal for HCMV diagnosis. Due to the lack of standardization in the production/purification of antigens from viral preparations, ELISA tests are based on several recombinant proteins or peptides. As an alternative, multiepitope proteins may be employed. OBJECTIVE In this work, we developed a recombinant multiepitope protein (rMEHCMV) for HCMV diagnosis based on conserved and immunodominant epitopes derived from tegument (pp150, pp65 and pp28), glycoprotein gB (pp38) and DNA polymerase subunit (pp52) of HCMV. METHODS The rMEHCMV gene was synthesized de novo and overexpressed in Escherichia coli cells. The recombinant protein was purified to homogeneity using a Ni-NTA column. Biophysical analysis of recombinant protein was performed by circular dichroism. A preliminary biological activity test was performed using 12 positive human sera samples by using an in-house IgG ELISA. The following patents database were consulted: Espacenet, Google Patents and the National Institute of Intellectual Property (INPI, Brazil). RESULTS The recombinant multiepitope protein was successfully expressed in E. coli. The structural data obtained by circular dichroism spectroscopy showed that rMEHCMV is structurally disordered. An in-house IgG ELISA test with rMEHCMV was successfully used to recognized IgG from human serum samples. CONCLUSION Together, our results show that rMEHCMV should be considered as a potential antigenic target for HCMV diagnosis.
Collapse
Affiliation(s)
- Patrícia A F Ribeiro
- Laboratorio de Biotecnologia de Microrganismos, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| | - Marilen Q Souza
- Departamento de Biologia Celular, Universidade de Brasilia, Brasília, DF, 70910-900, Brazil
| | - Daniel S Dias
- Laboratorio de Biotecnologia de Microrganismos, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| | - Alice C M Álvares
- Laboratorio de Biofisica, Universidade de Brasilia, Brasilia, DF, 70910-900, Brazil
| | - Laís M Nogueira
- Laboratorio de Biotecnologia de Microrganismos, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| | - Juliana M Machado
- Laboratorio de Biotecnologia de Microrganismos, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| | - José C Dos Santos
- Departamento de Biologia Celular, Universidade de Brasilia, Brasília, DF, 70910-900, Brazil
| | - Renato R Godoi
- Laboratorio de Biotecnologia de Microrganismos, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| | - Yanna K M Nobrega
- Laboratorio de Doencas Imunogeneticas e Cronico-degenerativas, Universidade de Brasilia, Brasilia, DF, 70910-900, Brazil
| | - Mariana Campos-da-Paz
- Laboratorio de Nanobiotecnologia, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| | - Sonia M de Freitas
- Laboratorio de Biofisica, Universidade de Brasilia, Brasilia, DF, 70910-900, Brazil
| | - Maria S S Felipe
- Departamento de Biologia Celular, Universidade de Brasilia, Brasília, DF, 70910-900, Brazil
| | - Fernando A G Torres
- Departamento de Biologia Celular, Universidade de Brasilia, Brasília, DF, 70910-900, Brazil
| | - Alexsandro S Galdino
- Laboratorio de Biotecnologia de Microrganismos, Universidade Federal de Sao Joao Del-Rei, Divinopolis, MG, 35501-296, Brazil
| |
Collapse
|
2
|
Pagnon A, Piras F, Gimenez-Fourage S, Dubayle J, Arnaud-Barbe N, Hessler C, Caillet C. Optimized enzyme-linked immunosorbent assay for detecting cytomegalovirus infections during clinical trials of recombinant vaccines. J Clin Virol 2017; 96:99-104. [PMID: 29035763 DOI: 10.1016/j.jcv.2017.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 10/03/2017] [Accepted: 10/07/2017] [Indexed: 11/18/2022]
Abstract
BACKGROUND In clinical trials of cytomegalovirus (CMV) glycoprotein B (gB) vaccines, CMV infection is detected by first depleting serum of anti-gB antibodies and then measuring anti-CMV antibodies with a commercially available enzyme-linked immunosorbent assay (ELISA) kit, with confirmation of positive findings by immunoblot. OBJECTIVES Identification of CMV immunoantigens for the development of an ELISA that detects specifically CMV infection in clinical samples from individuals immunized with gB vaccines. STUDY DESIGN Sensitivity and specificity of ELISAs using antigenic regions of CMV proteins UL83/pp65, UL99/pp28, UL44/pp52, UL80a/pp38, UL57, and UL32/pp150 were measured. RESULTS An IgG ELISA using a UL32/pp150 [862-1048] capture peptide was the most specific (93.7%) and sensitive (96.4%) for detecting CMV-specific antibodies in sera. The ELISA successfully detected CMV-specific antibodies in 22 of 22 sera of subjects who had been vaccinated with a gB vaccine but who had later been infected with CMV. The ELISA was linear over a wide range of CMV concentrations (57-16,814 ELISA units/mL) and was reproducible as indicated by a 5% intra-day and 7% inter-day coefficients of variation. The signal was specifically competed by UL32/pp150 [862-1048] peptide but not by CMV-gB or herpes simplex virus 2 glycoprotein D. Lipid and hemoglobin matrix did not interfere with the assay. CONCLUSION The UL32/pp150 [862-1048] IgG ELISA can be used for the sensitive and specific detection of CMV infection in gB-vaccinated individuals.
Collapse
|
3
|
Silvestri ME, Sundqvist VA. An investigation into the heparin-binding properties of a synthetic peptide deduced from the antigenic domain 2 of human cytomegalovirus glycoprotein B. Scand J Immunol 2001; 53:282-9. [PMID: 11251886 DOI: 10.1046/j.1365-3083.2001.00878.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
An investigation was performed into the heparin-binding properties of a synthetic peptide deduced from the sequence of human cytomegalovirus glycoprotein B. The peptide, T7-13:3, amino acids 69-78, which was previously shown to contain a neutralization epitope was able to bind heparin coated onto microtitre plates as well as immobilized on agarose beads. Conversely, labelled heparin could be used to specifically detect the immobilized peptide. The peptide bound to human cells in a manner which suggested an interaction with extracellular matrix, and binding of the peptide to human fibroblasts could be inhibited both by adding soluble heparin and by enzymatic pretreatment of the cells with heparinase. The sequence of T7-13:3 shows similarity to several proteins with known or supposed ability to bind heparin, e.g. basic fibroblast growth factor, the heparin-binding capacity of which could also be inhibited by T7-13:3. The peptide was also found to bind DNA, probably due to the similarities between DNA and heparin in terms of structure and charge. Because heparin is a chemical homologue of heparan sulfate, the results strongly indicate that the sequence represented by T7-13:3 is involved in the binding of virus to cell surface heparan sulfate. The described region of gB may have the potential to contribute to a subunit vaccine although possible hazards, such as the induction of auto-antibodies to heparin, and thus also to DNA, need to be considered.
Collapse
Affiliation(s)
- M E Silvestri
- Division of Biomedical Laboratory Technology, Department of Microbiology, Pathology and Immunology, Karolinska Institutet, PO Box 12 773, S-112 96 Stockholm, Sweden.
| | | |
Collapse
|
4
|
Daiminger A, Bäder U, Enders G. An enzyme linked immunoassay using recombinant antigens for differentiation of primary from secondary or past CMV infections in pregnancy. J Clin Virol 1998; 11:93-102. [PMID: 9785210 DOI: 10.1016/s1386-6532(98)00052-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
BACKGROUND As primary cytomegalovirus (CMV) infection in pregnancy may be associated with severe fetal outcome, the serological differentiation of primary infection from recurrent or previous infection is of major importance. OBJECTIVES This differentiation was attempted with a CMV IgG enzyme immunoassay (EIA), which investigated the differential IgG immune response to recombinant proteins p52 and pp150. To express the IgG reactivity to either protein a ratio was calculated by OD p52/OD pp150. STUDY DESIGN Serial samples from groups of pregnant women with primary infection (n = 18) were compared to those with recurrent (n = 7) or previous CMV infection (n = 189). RESULTS In primary infected women a predominant IgG response to p52 (p52 alone or ratio > or = 1.5) was observed in early sera less than 4 weeks after seroconversion, whereas the IgG response to recombinant protein pp150 was delayed and appeared after 2-7 weeks. Women with secondary and those with past infection had either IgG antibodies to pp150 alone or a ratio of less than 1.5 in 85 and 89.1% respectively with no remarkable change of ratio over time. CONCLUSIONS The IgG recombinant EIA was shown to be a useful supplementary assay for differentiation of primary up to 8 weeks after seroconversion from recurrent or past infections.
Collapse
Affiliation(s)
- A Daiminger
- Institut für Virologie, Infektiologie und Epidemiologie e.V., Stuttgart, Germany
| | | | | |
Collapse
|
5
|
Vornhagen R, Plachter B, Hinderer W, The TH, Van Zanten J, Matter L, Schmidt CA, Sonneborn HH, Jahn G. Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens. J Clin Microbiol 1994; 32:981-6. [PMID: 8027354 PMCID: PMC267166 DOI: 10.1128/jcm.32.4.981-986.1994] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
DNA fragments from eight different reading frames of human cytomegalovirus (HCMV) were generated by PCR and subsequently cloned and expressed in Escherichia coli in fusion with glutathione S-transferase. The recombinant viral antigens were evaluated in immunoblot analyses. The most reactive antigens were purified and further evaluated in ELISAs. For this, sera from healthy blood donors and immunocompetent individuals with acute HCMV infection, and follow-up sera from transplant recipients with acute primary HCMV infection were used. The results of our experiments indicate that only three particular recombinant polypeptides from two viral proteins are necessary for serodiagnosis. While a fragment covering amino acids (aa) 495 to 691 of pp150 (150/1) was the most suitable antigen for the identification of infected individuals in general, immunoglobulin M antibodies against the C-terminal parts of pp150 (aa 862 to 1048; 150/7) and p52 (aa 297 to 433; 52/3) proved to be excellent serological markers to monitor acute HCMV infection. The selected recombinant antigens enable the improvement of serodiagnosis of HCMV-related diseases, especially during the early stages of infection.
Collapse
|